Sanjay Sharma, MD
Medical Oncology · Fullerton, CANPI 1174609358
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $527,254 of the $668,211 with a category attached, or 78.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 19.9%. Reporting peaked in 2024 at $182,104 and has fallen 59.4% since, to $73,881 in 2025. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,705 payments — averaging $391.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$133K
- AstraZeneca$111K
- E.r. Squibb & Sons, L.L.C.$85K
- Regeneron Healthcare Solutions, Inc.$66K
- Merck$56K
- Amgen$51K
- plus $165K from 54 others
Across 695 payments — averaging $1309.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$467K
- Exelixis Inc.$343K
- Eli Lilly$73K
- Janssen Research & Development, LLC$25K
- Merck$1K
What the payments were for
- Consulting fees$42,3386%
- Speaking & faculty fees$527,25479%
- Travel & lodging$60,6579%
- Food & beverage$37,0796%
- Education$8820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$668,211 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 15 | $328,590 |
| ErleadaApalutamide | 14 | $196,148 |
| CalquenceAcalabrutinib Maleate | 12 | $176,745 |
| EliquisApixaban | 21 | $21,721 |
| XareltoRivaroxaban | 12 | $10,727 |
| Imatinib Mesylate | 12 | $8,836 |
| Anastrozole | 100 | $1,557 |
| Ondansetron Hcl | 36 | $1,427 |
| Prochlorperazine Maleate | 70 | $767 |
| Potassium Chloride | 15 | $433 |
| Hydroxyurea | 13 | $427 |
| Bicalutamide | 20 | $410 |
| Dexamethasone | 41 | $370 |
| Tamoxifen Citrate | 11 | $277 |
| Ondansetron OdtOndansetron | 13 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $634 | $328,59015 claims |
| Johnson & JohnsonErleada, Xarelto | $2,528 | $206,87526 claims |
| AstraZenecaCalquence | $111,249 | $176,74512 claims |
| PfizerEliquis | $24,140 | $21,72121 claims |
| Lilly USA, LLCOlanzapine | $2,715 | $8337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 379 medical oncology providers in California.
Other medical oncology in Fullerton
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.